Phase 3 Prostate Cancer Trial, Recruiting NCT07500701 Sponsor: Samsung Medical Center Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT07500701
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had surgery to fully remove the prostate (called a radical prostatectomy) to treat prostate cancer
  • People aged 20 years or older
  • People whose PSA blood test levels remain elevated after prostate removal surgery — specifically, levels between 0.1 and 1.0 ng/mL that have risen at least three times in a row
  • People who have already had a specialised type of scan called a PSMA PET/CT scan to investigate the rising PSA levels
  • People who are in generally good physical health and able to carry out daily activities with little or no limitation (confirm with trial site)

Who may not be able to join:

  • People whose scans or clinical assessment show signs of cancer returning in the local area, spreading to lymph nodes, or spreading to other parts of the body
  • People who had evidence of lymph node spread or distant spread of cancer at the time of their prostate removal surgery
  • People who have previously had radiation treatment to the pelvic area
  • People with certain conditions that can increase the risk of serious side effects from radiation, such as inflammatory bowel disease, lupus, scleroderma, or similar connective tissue disorders
  • People who have been diagnosed with, or had a return of, another type of cancer within the past 3 years — with the exception of certain skin cancers and thyroid cancer
  • People with uncontrolled or ongoing health conditions that the trial doctors consider unsuitable for participation, such as dementia, Alzheimer's disease, or stroke history (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-10-9933-2616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
6 March 2026
Est. completion
31 December 2034

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

5-year biochemical progression-free survival (bPFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov